Research Analysts Set Expectations for IRWD Q4 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research raised their Q4 2027 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a note issued to investors on Thursday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.03). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $1.10 per share.

A number of other equities analysts have also commented on IRWD. Wall Street Zen raised Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 22nd. Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.23.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $4.25 on Tuesday. Ironwood Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $5.78. The company has a market capitalization of $702.27 million, a price-to-earnings ratio of 5.52 and a beta of 0.20. The business has a 50-day moving average of $4.15 and a 200-day moving average of $3.89.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The company had revenue of $113.04 million during the quarter, compared to the consensus estimate of $114.84 million.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC raised its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the period. LSV Asset Management acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $30,000. Captrust Financial Advisors bought a new stake in Ironwood Pharmaceuticals in the 2nd quarter valued at about $32,000. Jump Financial LLC bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $34,000. Finally, DGS Capital Management LLC bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $35,000.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the sale, the insider directly owned 313,680 shares in the company, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Julie Mchugh sold 21,571 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This trade represents a 7.92% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 9.30% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.